Barbara Mullin is a Partner in Patterson Belknap’s Litigation department, with a focus on patent litigation. Ms. Mullin has over 25 years of experience litigating patent infringement disputes. She regularly tries patent cases in federal courts and before arbitration panels, and has argued before the Court of Appeals for the Federal Circuit. Her cases have involved diverse fields such as recombinant antibody technology, medical devices and methods, small molecule pharmaceuticals, semiconductor wafer processing, and water guns. In addition to representing clients in litigation and arbitration proceedings, Ms. Mullin also counsels innovator pharmaceutical and medical device clients on strategic patenting and licensing and freedom to operate issues, as well as Orange Book Listings, Paragraph IV certifications, and other ANDA-related matters.
Among Ms. Mullin’s successes, she obtained a significant trial victory for a Fortune 100 pharmaceutical company in a Hatch-Waxman patent litigation where patent validity was at issue. After a multi-week virtual bench trial, the District Court of New Jersey issued an order rejecting all of the defendant’s allegations of invalidity. At stake was nearly 10 years of patent protection for a blockbuster medicine with over $1.5 billion in annual sales in the United States. She also served as one of the principal attorneys representing a biotechnology company and private university in a patent trial charging a competitor’s product with infringement, where the jury returned a verdict that her clients’ patent was willfully infringed and not invalid, leading to a damages award of $1.67 billion. Ms. Mullin was selected as The American Lawyer’s ‘Litigator of the Week’ for securing this significant trial victory.
Ms. Mullin is a frequent speaker on topics related to patent litigation. She earned her J.D., cum laude, from Villanova University School of Law and received her B.S., cum laude, from The University of Pennsylvania.
Updated Aug 2024
